Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer

Susan Halabi, William Kevin Kelly, Hua Ma, Haojin Zhou, Nicole C. Solomon, Karim Fizazi, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Maha Hussain, Nicholas J. Vogelzang, Ian M. Thompson, Kim N. Chi, Johann De Bono, Andrew J. Armstrong, Mario A. Eisenberger, Abderrahim Fandi, Shaoyi Li, John C. Araujo, Christopher J. Logothetis & 5 others David I. Quinn, Michael J. Morris, Celestia S. Higano, Ian F. Tannock, Eric J. Small

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Purpose Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients.Weinvestigate the impact of site of metastases on OS of a substantial sample of men with mCRPC who received docetaxel chemotherapy in nine phase III trials. Patients and Methods Individual patient data from 8,820 men with mCRPC enrolled onto nine phase III trials were combined. Site of metastases was categorized as lymph node (LN) only, bone with or without LN (with no visceral metastases), any lung metastases (but no liver), and any liver metastases. Results Most patients had bone with or without LN metastases (72.8%), followed by visceral disease (20.8%) and LN-only disease (6.4%). Men with liver metastases had the worst median OS (13.5 months). Although menwith lungmetastases had bettermedian OS (19.4months) compared with menwith liver metastases, they had significantly worse median survival duration than men with nonvisceral bone metastases (21.3 months). Men with LN-only disease had a median OS of 31.6 months. The pooled hazard ratios for death in men with lung metastases compared with men with bone with or without LN metastases and in men with any liver metastases compared withmen with lung metastases were 1.14 (95% CI, 1.04 to 1.25; P = .007) and 1.52 (95% CI, 1.35 to 1.73; P , .0001), respectively. Conclusion Specific sites of metastases in men with mCRPC are associated with differential OS, with successive increased lethality for lung and liver metastases compared with bone and nonvisceral involvement. These data may help in treatment decisions, the design of future clinical trials, and understanding the variation in biology of different sites of metastases in men with mCRPC.A.

Original languageEnglish (US)
Pages (from-to)1652-1659
Number of pages8
JournalJournal of Clinical Oncology
Volume34
Issue number14
DOIs
StatePublished - May 10 2016
Externally publishedYes

Fingerprint

Castration
Meta-Analysis
Prostatic Neoplasms
Neoplasm Metastasis
Survival
Lymph Nodes
Liver
Bone and Bones
Lung
docetaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. / Halabi, Susan; Kelly, William Kevin; Ma, Hua; Zhou, Haojin; Solomon, Nicole C.; Fizazi, Karim; Tangen, Catherine M.; Rosenthal, Mark; Petrylak, Daniel P.; Hussain, Maha; Vogelzang, Nicholas J.; Thompson, Ian M.; Chi, Kim N.; De Bono, Johann; Armstrong, Andrew J.; Eisenberger, Mario A.; Fandi, Abderrahim; Li, Shaoyi; Araujo, John C.; Logothetis, Christopher J.; Quinn, David I.; Morris, Michael J.; Higano, Celestia S.; Tannock, Ian F.; Small, Eric J.

In: Journal of Clinical Oncology, Vol. 34, No. 14, 10.05.2016, p. 1652-1659.

Research output: Contribution to journalArticle

Halabi, S, Kelly, WK, Ma, H, Zhou, H, Solomon, NC, Fizazi, K, Tangen, CM, Rosenthal, M, Petrylak, DP, Hussain, M, Vogelzang, NJ, Thompson, IM, Chi, KN, De Bono, J, Armstrong, AJ, Eisenberger, MA, Fandi, A, Li, S, Araujo, JC, Logothetis, CJ, Quinn, DI, Morris, MJ, Higano, CS, Tannock, IF & Small, EJ 2016, 'Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer', Journal of Clinical Oncology, vol. 34, no. 14, pp. 1652-1659. https://doi.org/10.1200/JCO.2015.65.7270
Halabi, Susan ; Kelly, William Kevin ; Ma, Hua ; Zhou, Haojin ; Solomon, Nicole C. ; Fizazi, Karim ; Tangen, Catherine M. ; Rosenthal, Mark ; Petrylak, Daniel P. ; Hussain, Maha ; Vogelzang, Nicholas J. ; Thompson, Ian M. ; Chi, Kim N. ; De Bono, Johann ; Armstrong, Andrew J. ; Eisenberger, Mario A. ; Fandi, Abderrahim ; Li, Shaoyi ; Araujo, John C. ; Logothetis, Christopher J. ; Quinn, David I. ; Morris, Michael J. ; Higano, Celestia S. ; Tannock, Ian F. ; Small, Eric J. / Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 14. pp. 1652-1659.
@article{a38d09c6ec324bac93ad03d2aa43bbad,
title = "Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer",
abstract = "Purpose Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients.Weinvestigate the impact of site of metastases on OS of a substantial sample of men with mCRPC who received docetaxel chemotherapy in nine phase III trials. Patients and Methods Individual patient data from 8,820 men with mCRPC enrolled onto nine phase III trials were combined. Site of metastases was categorized as lymph node (LN) only, bone with or without LN (with no visceral metastases), any lung metastases (but no liver), and any liver metastases. Results Most patients had bone with or without LN metastases (72.8{\%}), followed by visceral disease (20.8{\%}) and LN-only disease (6.4{\%}). Men with liver metastases had the worst median OS (13.5 months). Although menwith lungmetastases had bettermedian OS (19.4months) compared with menwith liver metastases, they had significantly worse median survival duration than men with nonvisceral bone metastases (21.3 months). Men with LN-only disease had a median OS of 31.6 months. The pooled hazard ratios for death in men with lung metastases compared with men with bone with or without LN metastases and in men with any liver metastases compared withmen with lung metastases were 1.14 (95{\%} CI, 1.04 to 1.25; P = .007) and 1.52 (95{\%} CI, 1.35 to 1.73; P , .0001), respectively. Conclusion Specific sites of metastases in men with mCRPC are associated with differential OS, with successive increased lethality for lung and liver metastases compared with bone and nonvisceral involvement. These data may help in treatment decisions, the design of future clinical trials, and understanding the variation in biology of different sites of metastases in men with mCRPC.A.",
author = "Susan Halabi and Kelly, {William Kevin} and Hua Ma and Haojin Zhou and Solomon, {Nicole C.} and Karim Fizazi and Tangen, {Catherine M.} and Mark Rosenthal and Petrylak, {Daniel P.} and Maha Hussain and Vogelzang, {Nicholas J.} and Thompson, {Ian M.} and Chi, {Kim N.} and {De Bono}, Johann and Armstrong, {Andrew J.} and Eisenberger, {Mario A.} and Abderrahim Fandi and Shaoyi Li and Araujo, {John C.} and Logothetis, {Christopher J.} and Quinn, {David I.} and Morris, {Michael J.} and Higano, {Celestia S.} and Tannock, {Ian F.} and Small, {Eric J.}",
year = "2016",
month = "5",
day = "10",
doi = "10.1200/JCO.2015.65.7270",
language = "English (US)",
volume = "34",
pages = "1652--1659",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "14",

}

TY - JOUR

T1 - Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer

AU - Halabi, Susan

AU - Kelly, William Kevin

AU - Ma, Hua

AU - Zhou, Haojin

AU - Solomon, Nicole C.

AU - Fizazi, Karim

AU - Tangen, Catherine M.

AU - Rosenthal, Mark

AU - Petrylak, Daniel P.

AU - Hussain, Maha

AU - Vogelzang, Nicholas J.

AU - Thompson, Ian M.

AU - Chi, Kim N.

AU - De Bono, Johann

AU - Armstrong, Andrew J.

AU - Eisenberger, Mario A.

AU - Fandi, Abderrahim

AU - Li, Shaoyi

AU - Araujo, John C.

AU - Logothetis, Christopher J.

AU - Quinn, David I.

AU - Morris, Michael J.

AU - Higano, Celestia S.

AU - Tannock, Ian F.

AU - Small, Eric J.

PY - 2016/5/10

Y1 - 2016/5/10

N2 - Purpose Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients.Weinvestigate the impact of site of metastases on OS of a substantial sample of men with mCRPC who received docetaxel chemotherapy in nine phase III trials. Patients and Methods Individual patient data from 8,820 men with mCRPC enrolled onto nine phase III trials were combined. Site of metastases was categorized as lymph node (LN) only, bone with or without LN (with no visceral metastases), any lung metastases (but no liver), and any liver metastases. Results Most patients had bone with or without LN metastases (72.8%), followed by visceral disease (20.8%) and LN-only disease (6.4%). Men with liver metastases had the worst median OS (13.5 months). Although menwith lungmetastases had bettermedian OS (19.4months) compared with menwith liver metastases, they had significantly worse median survival duration than men with nonvisceral bone metastases (21.3 months). Men with LN-only disease had a median OS of 31.6 months. The pooled hazard ratios for death in men with lung metastases compared with men with bone with or without LN metastases and in men with any liver metastases compared withmen with lung metastases were 1.14 (95% CI, 1.04 to 1.25; P = .007) and 1.52 (95% CI, 1.35 to 1.73; P , .0001), respectively. Conclusion Specific sites of metastases in men with mCRPC are associated with differential OS, with successive increased lethality for lung and liver metastases compared with bone and nonvisceral involvement. These data may help in treatment decisions, the design of future clinical trials, and understanding the variation in biology of different sites of metastases in men with mCRPC.A.

AB - Purpose Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients.Weinvestigate the impact of site of metastases on OS of a substantial sample of men with mCRPC who received docetaxel chemotherapy in nine phase III trials. Patients and Methods Individual patient data from 8,820 men with mCRPC enrolled onto nine phase III trials were combined. Site of metastases was categorized as lymph node (LN) only, bone with or without LN (with no visceral metastases), any lung metastases (but no liver), and any liver metastases. Results Most patients had bone with or without LN metastases (72.8%), followed by visceral disease (20.8%) and LN-only disease (6.4%). Men with liver metastases had the worst median OS (13.5 months). Although menwith lungmetastases had bettermedian OS (19.4months) compared with menwith liver metastases, they had significantly worse median survival duration than men with nonvisceral bone metastases (21.3 months). Men with LN-only disease had a median OS of 31.6 months. The pooled hazard ratios for death in men with lung metastases compared with men with bone with or without LN metastases and in men with any liver metastases compared withmen with lung metastases were 1.14 (95% CI, 1.04 to 1.25; P = .007) and 1.52 (95% CI, 1.35 to 1.73; P , .0001), respectively. Conclusion Specific sites of metastases in men with mCRPC are associated with differential OS, with successive increased lethality for lung and liver metastases compared with bone and nonvisceral involvement. These data may help in treatment decisions, the design of future clinical trials, and understanding the variation in biology of different sites of metastases in men with mCRPC.A.

UR - http://www.scopus.com/inward/record.url?scp=84971006454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971006454&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.65.7270

DO - 10.1200/JCO.2015.65.7270

M3 - Article

VL - 34

SP - 1652

EP - 1659

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 14

ER -